Research & Development July 3, 2026 SK bioscience to lead Gates Foundation-funded ROTOR project By Salong Debbarma The project will involve collaboration with global health organisation PATH and consulting firm Slalom. The initiative seeks to create a platform that uses AI to analyse a wide
Research & Development July 3, 2026 European Commission approves Novartis’ Itvisma to treat SMA By Salong Debbarma With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional
Research & Development July 2, 2026 Insilico Medicine, Takeda partner on AI-driven drug discovery By Salong Debbarma Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Takeda will take the lead in advancing selected
OncologyResearch & Development July 2, 2026 Inocras, AimedBio team up for cancer treatments By Salong Debbarma The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of
Research & DevelopmentApprovals July 1, 2026 US FDA rejects approval of Unicycive’s kidney disease therapy By Salong Debbarma This decision was issued in a Complete Response Letter (CRL) which cited deficiencies at a third-party manufacturing facility producing OLC. The FDA did not raise concerns related to
Research & DevelopmentRegulation July 1, 2026 Eli Lilly and Innovent agree Verzenios commercialisation deal in China By Salong Debbarma Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios
OncologyApprovals June 30, 2026 Anixa Biosciences secures Korean patent for breast cancer vaccine By Salong Debbarma The MOIP has issued Patent Number 10-2960889, providing protection for Anixa’s breast cancer vaccine approach in South Korea through 2040. This specific composition-of-matter patent is exclusively licensed from
Research & Development June 30, 2026 Zymeworks agrees to buy Theravance Biopharma for $929m By Salong Debbarma Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of
Research & Development June 29, 2026 FDA issues complete response letter to Sobi’s NASP for gout By Salong Debbarma The FDA has requested further information, primarily focusing on the manufacturing control strategy of the biological component of NASP and on deficiencies related to contract manufacturing facilities. It
Research & Development June 29, 2026 Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe By Salong Debbarma This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, regardless of previous Bruton tyrosine kinase (BTK) inhibitor treatment. Following this recommendation, the Jaypirca application moves